Clincosm LogoSign in Get a demo

Renal Cell Carcinoma

Showing NaN - NaN of 65
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer Trial in United States (NKTR-262, bempegaldesleukin, nivolumab)

Terminated
  • Melanoma
  • +6 more
  • Scottsdale, Arizona
  • +13 more
Jun 24, 2022

Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer Trial in Worldwide (Combination of NKTR-214 + nivolumab)

Completed
  • Melanoma
  • +6 more
  • Combination of NKTR-214 + nivolumab
  • La Jolla, California
  • +57 more
Jun 22, 2022

Pancreatic Cancer, Breast Cancer, Gastric Cancer Trial in United States (NGM831, NGM831 plus pembrolizumab)

Recruiting
  • Pancreatic Cancer
  • +15 more
  • Gilbert, Arizona
  • +4 more
Jun 21, 2022

Melanoma, Renal Cell Carcinoma, NSCLC Trial in United States (HBI-8000 in combination with nivolumab)

Active, not recruiting
  • Melanoma
  • +2 more
  • HBI-8000 in combination with nivolumab
  • Phoenix, Arizona
  • +5 more
Jun 11, 2022

Adrenal Cortex Carcinoma, Alveolar Soft Part Sarcoma, CNS Tumor Trial in United States (Cabozantinib, Cabozantinib S-malate,

Active, not recruiting
  • Adrenal Cortex Carcinoma
  • +39 more
  • Birmingham, Alabama
  • +142 more
May 24, 2022

Thyroid, Renal Cell Carcinoma, Non Small Cell Lung Cancer Trial in Worldwide (SO-C101, pembrolizumab)

Recruiting
  • Thyroid
  • +18 more
  • New Haven, Connecticut
  • +6 more
Apr 8, 2022

NSCLC, Small Cell Lung Cancer, Urothelial Carcinoma Trial in United States (N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 +

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • +12 more
  • N-803 + Pembrolizumab
  • +9 more
  • Anchorage, Alaska
  • +34 more
Apr 4, 2022

Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma Trial in Worldwide (bempegaldesleukin, sunitinib, nivolumab)

Active, not recruiting
  • Renal Cell Carcinoma
  • Metastatic Renal Cell Carcinoma
  • bempegaldesleukin
  • +3 more
  • Anchorage, Alaska
  • +108 more
Mar 31, 2022

Breast Cancer, Renal Cell Carcinoma Trial in United States (IPI-549 (eganelisib), Atezolizumab, nab-paclitaxel)

Active, not recruiting
  • Breast Cancer
  • Renal Cell Carcinoma
  • IPI-549 (eganelisib)
  • +3 more
  • Chandler, Arizona
  • +23 more
Apr 1, 2022

Advanced Solid Tumors, Head Neck Cancer, Pancreatic Cancer Trial in United States (Cabiralizumab, Nivolumab)

Completed
Has Results
  • Advanced Solid Tumors
  • +6 more
  • Cabiralizumab
  • Nivolumab
  • Scottsdale, Arizona
  • +38 more
Jan 5, 2022

Solid Tumor, Microsatellite Stable Colorectal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma Trial in Canada, Korea,

Recruiting
  • Solid Tumor
  • +8 more
  • TBio-6517
  • Pembrolizumab
  • Phoenix, Arizona
  • +10 more
Feb 21, 2022

Follow-up After Metastasectomy in Patients With Kidney Cancer

Active, not recruiting
  • Renal Cell Carcinoma
  • Follow-Up Care
  • Laboratory Biomarker Analysis
  • Houston, Texas
    M D Anderson Cancer Center
Feb 25, 2022

Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer Trial in Worldwide (SL-279252)

Recruiting
  • Squamous Cell Carcinoma of the Head and Neck
  • +12 more
  • Nashville, Tennessee
  • +4 more
Feb 3, 2022

Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma Trial in Canada, United States (Nivolumab, Pazopanib,

Completed
Has Results
  • Renal Cell Carcinoma
  • Clear-cell Metastatic Renal Cell Carcinoma
  • Nivolumab
  • +3 more
  • Duarte, California
  • +13 more
Nov 30, 2021

Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v8, Stage II Renal Cell Cancer AJCC v8 Trial in Houston (procedure, other,

Withdrawn
  • Renal Cell Carcinoma
  • +2 more
  • Magnetic Resonance Imaging
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 18, 2021

Long-term, Non-interventional, Observational Study Following

Recruiting
  • Advanced Solid Tumor
  • +17 more
  • Allogeneic natural killer (NK) cell
  • San Diego, California
  • +3 more
Oct 15, 2021

Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma Trial in United States (XmAb®23104, Yervoy®

Recruiting
  • Melanoma (Excluding Uveal Melanoma)
  • +15 more
  • XmAb®23104
  • Yervoy® (ipilimumab)
  • San Diego, California
  • +15 more
Sep 20, 2021

Disease Burden and Biology Using Tumor Cell Free DNA in

Recruiting
  • Renal Cell Carcinoma
  • Blood collection
  • Urine collection
  • Nashville, Tennessee
  • +2 more
Sep 1, 2021

Renal Cell Carcinoma Trial in Albany, Houston, Quebec (HSPPC-96)

Terminated
Has Results
  • Renal Cell Carcinoma
  • HSPPC-96
  • Albany, New York
  • +2 more
May 10, 2021

Renal Cell Carcinoma Trial in Worldwide (Cabozantinib tablets, Everolimus (Afinitor) tablets)

Completed
Has Results
  • Renal Cell Carcinoma
  • Cabozantinib tablets
  • Everolimus (Afinitor) tablets
  • Birmingham, Alabama
  • +204 more
Apr 1, 2021

Epithelial Ovarian Cancer, Renal Cell Carcinoma Trial in Worldwide (HKT288)

Terminated
  • Epithelial Ovarian Cancer
  • Renal Cell Carcinoma
  • Houston, Texas
  • +5 more
Dec 6, 2020

Renal Cell Carcinoma, Kidney Cancer Trial in Houston (Bevacizumab)

Completed
Has Results
  • Renal Cell Carcinoma
  • Kidney Cancer
  • Houston, Texas
    UT MD Anderson Cancer Center
Sep 1, 2020

Hematological Tumors, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma Trial in United States (CC-486, Vidaza)

Completed
  • Hematological Neoplasms
  • +19 more
  • Scottsdale, Arizona
  • +9 more
May 11, 2020

Genetic Susceptibility to Kidney Cancer

Terminated
  • Renal Cell Carcinoma
    • Houston, Texas
      MD Anderson Cancer Center
    Feb 21, 2020

    Renal Cell Carcinoma, Kidney Cancer Trial in United States (124-Iodine-cG250 (124I-cG250), CT)

    Completed
    Has Results
    • Renal Cell Carcinoma
    • Kidney Cancer
    • 124-Iodine-cG250 (124I-cG250)
    • CT
    • Los Angeles, California
    • +13 more
    Sep 3, 2018